CN101461526A - 具有保肝解酒作用的保健品及其制备方法 - Google Patents
具有保肝解酒作用的保健品及其制备方法 Download PDFInfo
- Publication number
- CN101461526A CN101461526A CNA2008103057858A CN200810305785A CN101461526A CN 101461526 A CN101461526 A CN 101461526A CN A2008103057858 A CNA2008103057858 A CN A2008103057858A CN 200810305785 A CN200810305785 A CN 200810305785A CN 101461526 A CN101461526 A CN 101461526A
- Authority
- CN
- China
- Prior art keywords
- parts
- liver
- effect
- health
- protecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 230000036541 health Effects 0.000 title claims description 15
- 230000006870 function Effects 0.000 title abstract description 8
- 230000000694 effects Effects 0.000 claims abstract description 26
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 10
- 244000062241 Kaempferia galanga Species 0.000 claims abstract description 8
- 235000013421 Kaempferia galanga Nutrition 0.000 claims abstract description 8
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims abstract description 7
- 239000009636 Huang Qi Substances 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 9
- 244000157790 Buglossoides arvense Species 0.000 claims description 6
- 235000004256 Buglossoides arvense Nutrition 0.000 claims description 6
- 244000241872 Lycium chinense Species 0.000 claims description 6
- 235000015468 Lycium chinense Nutrition 0.000 claims description 6
- 235000013399 edible fruits Nutrition 0.000 claims description 6
- 235000012907 honey Nutrition 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 35
- 210000004185 liver Anatomy 0.000 abstract description 9
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 244000046146 Pueraria lobata Species 0.000 abstract description 2
- 235000010575 Pueraria lobata Nutrition 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 241001071917 Lithospermum Species 0.000 abstract 1
- 235000017784 Mespilus germanica Nutrition 0.000 abstract 1
- 244000182216 Mimusops elengi Species 0.000 abstract 1
- 235000000560 Mimusops elengi Nutrition 0.000 abstract 1
- 235000007837 Vangueria infausta Nutrition 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000008267 milk Substances 0.000 abstract 1
- 210000004080 milk Anatomy 0.000 abstract 1
- 235000013336 milk Nutrition 0.000 abstract 1
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 8
- MQVRGDZCYDEQML-UHFFFAOYSA-N Astragalin Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 MQVRGDZCYDEQML-UHFFFAOYSA-N 0.000 description 6
- RSAHICAPUYTWHW-UHFFFAOYSA-N Hexahydrocurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(O)CC(=O)CCC=2C=C(OC)C(O)=CC=2)=C1 RSAHICAPUYTWHW-UHFFFAOYSA-N 0.000 description 6
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 6
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 6
- -1 methyl hexyl Chemical group 0.000 description 6
- 235000005875 quercetin Nutrition 0.000 description 6
- 229960001285 quercetin Drugs 0.000 description 6
- 241001061264 Astragalus Species 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 235000006533 astragalus Nutrition 0.000 description 5
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 description 5
- 229930182470 glycoside Natural products 0.000 description 5
- 150000002338 glycosides Chemical class 0.000 description 5
- JPUKWEQWGBDDQB-QSOFNFLRSA-N kaempferol 3-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=CC(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O JPUKWEQWGBDDQB-QSOFNFLRSA-N 0.000 description 5
- 210000004233 talus Anatomy 0.000 description 5
- 230000008673 vomiting Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- OELMAFBLFOKZJD-UHFFFAOYSA-N 1,7-bis(4-hydroxy-3-methoxyphenyl)heptane-3,5-diol Chemical compound C1=C(O)C(OC)=CC(CCC(O)CC(O)CCC=2C=C(OC)C(O)=CC=2)=C1 OELMAFBLFOKZJD-UHFFFAOYSA-N 0.000 description 4
- LYISDADPVOHJBJ-UHFFFAOYSA-N 3-methylgalangin Chemical compound O1C2=CC(O)=CC(O)=C2C(=O)C(OC)=C1C1=CC=CC=C1 LYISDADPVOHJBJ-UHFFFAOYSA-N 0.000 description 4
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 4
- 239000005770 Eugenol Substances 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- OQAGVSWESNCJJT-UHFFFAOYSA-N Methyl 3-methylbutanoate Chemical compound COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 description 4
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 4
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229960002217 eugenol Drugs 0.000 description 4
- VCCRNZQBSJXYJD-UHFFFAOYSA-N galangin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=CC=C1 VCCRNZQBSJXYJD-UHFFFAOYSA-N 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- SQFSKOYWJBQGKQ-UHFFFAOYSA-N kaempferide Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 SQFSKOYWJBQGKQ-UHFFFAOYSA-N 0.000 description 4
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 4
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- MQSZRBPYXNEFHF-UHFFFAOYSA-N rhamnocitrin Chemical compound C=1C(OC)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C=C1 MQSZRBPYXNEFHF-UHFFFAOYSA-N 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 241000723353 Chrysanthemum Species 0.000 description 3
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 3
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000002929 anti-fatigue Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 229930182478 glucoside Natural products 0.000 description 3
- 150000008131 glucosides Chemical class 0.000 description 3
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 3
- 235000008800 isorhamnetin Nutrition 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002417 nutraceutical Substances 0.000 description 3
- 235000021436 nutraceutical agent Nutrition 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 206010036067 polydipsia Diseases 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 235000017709 saponins Nutrition 0.000 description 3
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 2
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 2
- UDNMYDZHPMNIEQ-UHFFFAOYSA-N 4-Hepten-3-one, 1,7-diphenyl- Chemical compound C=1C=CC=CC=1CCC=CC(=O)CCC1=CC=CC=C1 UDNMYDZHPMNIEQ-UHFFFAOYSA-N 0.000 description 2
- JHJPDDBIHSFERA-UHFFFAOYSA-N 5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-phenyl-3-heptanone Chemical compound C1=C(O)C(OC)=CC(CCC(O)CC(=O)CCC=2C=CC=CC=2)=C1 JHJPDDBIHSFERA-UHFFFAOYSA-N 0.000 description 2
- NOHMOWQGVDSLNY-UHFFFAOYSA-N 7-(4-hydroxy-3-methoxyphenyl)-1-phenylhept-4-en-3-one Chemical compound C1=C(O)C(OC)=CC(CCC=CC(=O)CCC=2C=CC=CC=2)=C1 NOHMOWQGVDSLNY-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 229930191576 Biochanin Natural products 0.000 description 2
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 2
- 244000192528 Chrysanthemum parthenium Species 0.000 description 2
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- BJBUTJQYZDYRMJ-UHFFFAOYSA-N Kaempferol 3,7-dimethyl ether Chemical compound C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(O)C=C1 BJBUTJQYZDYRMJ-UHFFFAOYSA-N 0.000 description 2
- 229930185135 Kaikasaponin Natural products 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- MGJLSBDCWOSMHL-WFMNFSIZSA-N Ononin Natural products O(C)c1ccc(C=2C(=O)c3c(OC=2)cc(O[C@H]2[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O2)cc3)cc1 MGJLSBDCWOSMHL-WFMNFSIZSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- NTFQHAKUNDRGJR-UHFFFAOYSA-N Sophoradiol Natural products CC1(C)CC(O)C2(C)CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1 NTFQHAKUNDRGJR-UHFFFAOYSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- RJBAXROZAXAEEM-UHFFFAOYSA-N azaleatin Chemical compound OC=1C(=O)C=2C(OC)=CC(O)=CC=2OC=1C1=CC=C(O)C(O)=C1 RJBAXROZAXAEEM-UHFFFAOYSA-N 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- WUADCCWRTIWANL-UHFFFAOYSA-N biochanin A Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O WUADCCWRTIWANL-UHFFFAOYSA-N 0.000 description 2
- LFEUICHQZGNOHD-RECXWPGBSA-N biochanin A 7-O-beta-D-glucoside Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC(O)=C2C1=O LFEUICHQZGNOHD-RECXWPGBSA-N 0.000 description 2
- MUYJSOCNDLUHPJ-UHFFFAOYSA-N bishydrocurcumin Natural products C1=C(O)C(OC)=CC(CCC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 MUYJSOCNDLUHPJ-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- ZZAJQOPSWWVMBI-UHFFFAOYSA-N calycosin Chemical compound C1=C(O)C(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZZAJQOPSWWVMBI-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- CCRCUPLGCSFEDV-UHFFFAOYSA-N cinnamic acid methyl ester Natural products COC(=O)C=CC1=CC=CC=C1 CCRCUPLGCSFEDV-UHFFFAOYSA-N 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 229940109262 curcumin Drugs 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 2
- MUYJSOCNDLUHPJ-XVNBXDOJSA-N dihydrocurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 MUYJSOCNDLUHPJ-XVNBXDOJSA-N 0.000 description 2
- BWHPKBOLJFNCPW-UHFFFAOYSA-N dihydrocurcumin Natural products C1=C(O)C(OC)=CC(CCC(=O)C=C(O)C=CC=2C=C(OC)C(O)=CC=2)=C1 BWHPKBOLJFNCPW-UHFFFAOYSA-N 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012259 ether extract Substances 0.000 description 2
- 235000008384 feverfew Nutrition 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 description 2
- CIPSYTVGZURWPT-UHFFFAOYSA-N galangin Natural products OC1=C(Oc2cc(O)c(O)cc2C1=O)c3ccccc3 CIPSYTVGZURWPT-UHFFFAOYSA-N 0.000 description 2
- 229940045109 genistein Drugs 0.000 description 2
- 235000006539 genistein Nutrition 0.000 description 2
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 2
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000010224 hepatic metabolism Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- PVJNLMXWZXXHSZ-UHFFFAOYSA-N izalpinin Natural products C=1C(OC)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=CC=C1 PVJNLMXWZXXHSZ-UHFFFAOYSA-N 0.000 description 2
- 235000008777 kaempferol Nutrition 0.000 description 2
- 229930007744 linalool Natural products 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- NUKZAGXMHTUAFE-UHFFFAOYSA-N methyl hexanoate Chemical compound CCCCCC(=O)OC NUKZAGXMHTUAFE-UHFFFAOYSA-N 0.000 description 2
- 229940017219 methyl propionate Drugs 0.000 description 2
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 2
- VSMOENVRRABVKN-UHFFFAOYSA-N oct-1-en-3-ol Chemical compound CCCCCC(O)C=C VSMOENVRRABVKN-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- MGJLSBDCWOSMHL-MIUGBVLSSA-N ononin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=C2C1=O MGJLSBDCWOSMHL-MIUGBVLSSA-N 0.000 description 2
- MGJLSBDCWOSMHL-UHFFFAOYSA-N ononoside Natural products C1=CC(OC)=CC=C1C1=COC2=CC(OC3C(C(O)C(O)C(CO)O3)O)=CC=C2C1=O MGJLSBDCWOSMHL-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- SUYJZKRQHBQNCA-UHFFFAOYSA-N pinobanksin Natural products O1C2=CC(O)=CC(O)=C2C(=O)C(O)C1C1=CC=CC=C1 SUYJZKRQHBQNCA-UHFFFAOYSA-N 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- ZEGUWBQDYDXBNS-FVFJQADASA-N sophoradiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)[C@H](O)CC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C ZEGUWBQDYDXBNS-FVFJQADASA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 150000008130 triterpenoid saponins Chemical class 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 235000014101 wine Nutrition 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- FWNZEKQVBDXWKA-ZCWREFTMSA-N (2r,5s)-2-[[(3s,8s,9s,10r,13r,14s,17r)-17-[(2r,5r)-5,6-dimethylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](C)C(C)C)[C@@H]1OC(CO)[C@@H](O)C(O)C1O FWNZEKQVBDXWKA-ZCWREFTMSA-N 0.000 description 1
- QBLFZIBJXUQVRF-UHFFFAOYSA-N (4-bromophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Br)C=C1 QBLFZIBJXUQVRF-UHFFFAOYSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- VSMOENVRRABVKN-MRVPVSSYSA-N 1-Octen-3-ol Natural products CCCCC[C@H](O)C=C VSMOENVRRABVKN-MRVPVSSYSA-N 0.000 description 1
- 102000001707 3',5'-Cyclic-AMP Phosphodiesterases Human genes 0.000 description 1
- 108010054479 3',5'-Cyclic-AMP Phosphodiesterases Proteins 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- YDXQPTHHAPCTPP-UHFFFAOYSA-N 3-Octen-1-ol Natural products CCCCC=CCCO YDXQPTHHAPCTPP-UHFFFAOYSA-N 0.000 description 1
- QXDWRXCXHXYLNC-UHFFFAOYSA-N 4-phenylheptan-4-ylbenzene Chemical class C=1C=CC=CC=1C(CCC)(CCC)C1=CC=CC=C1 QXDWRXCXHXYLNC-UHFFFAOYSA-N 0.000 description 1
- QTVAYNGFFDZGDR-CIJVEFAYSA-N 5-hydroxy-6-methoxy-3-(4-methoxyphenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)O3)O)=C(OC)C(O)=C2C1=O QTVAYNGFFDZGDR-CIJVEFAYSA-N 0.000 description 1
- UXQHNHMMYMGPAH-UHFFFAOYSA-N 6-hydroxy-3-(4-hydroxyphenyl)-7-methoxychromen-4-one Chemical compound O=C1C=2C=C(O)C(OC)=CC=2OC=C1C1=CC=C(O)C=C1 UXQHNHMMYMGPAH-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- NEZONWMXZKDMKF-JTQLQIEISA-N Alkannin Chemical compound C1=CC(O)=C2C(=O)C([C@@H](O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-JTQLQIEISA-N 0.000 description 1
- 239000004229 Alkannin Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- KFFJPIQLAPHYBF-UHFFFAOYSA-N Azukisaponin V Natural products COC(=O)C1OC(OC2CCC3(C)C(CCC4(C)C3CC=C5C6CC(C)(C)CC(O)C6(O)CCC45C)C2(C)CO)C(OC7OC(CO)C(O)C(O)C7OC8OC(C)C(O)C(O)C8O)C(O)C1O KFFJPIQLAPHYBF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010023832 Florigen Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 244000050403 Iris x germanica Species 0.000 description 1
- 235000002971 Iris x germanica Nutrition 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- QURCVMIEKCOAJU-HWKANZROSA-N Isoferulic acid Natural products COC1=CC=C(\C=C\C(O)=O)C=C1O QURCVMIEKCOAJU-HWKANZROSA-N 0.000 description 1
- 244000062250 Kaempferia rotunda Species 0.000 description 1
- 235000013422 Kaempferia rotunda Nutrition 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FSBIGDSBMBYOPN-VKHMYHEASA-N L-canavanine Chemical compound OC(=O)[C@@H](N)CCONC(N)=N FSBIGDSBMBYOPN-VKHMYHEASA-N 0.000 description 1
- CMUNUTVVOOHQPW-LURJTMIESA-N L-proline betaine Chemical compound C[N+]1(C)CCC[C@H]1C([O-])=O CMUNUTVVOOHQPW-LURJTMIESA-N 0.000 description 1
- 101710094902 Legumin Proteins 0.000 description 1
- 241000244365 Ligusticum sinense Species 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- FSBIGDSBMBYOPN-UHFFFAOYSA-N O-guanidino-DL-homoserine Natural products OC(=O)C(N)CCON=C(N)N FSBIGDSBMBYOPN-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- DCTLJGWMHPGCOS-UHFFFAOYSA-N Osajin Chemical compound C1=2C=CC(C)(C)OC=2C(CC=C(C)C)=C(O)C(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DCTLJGWMHPGCOS-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- OUZCFMSJGDEXRT-UHFFFAOYSA-N Scandinone Natural products O=C1C=2C(OC)=C(CC=C(C)C)C=3OC(C)(C)C=CC=3C=2OC=C1C1=CC=C(O)C=C1 OUZCFMSJGDEXRT-UHFFFAOYSA-N 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229930187719 Soyasaponin Natural products 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010044546 Traumatic ulcer Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- WNFXUXZJJKTDOZ-HNNXBMFYSA-N [(1s)-1-(5,8-dihydroxy-1,4-dioxonaphthalen-2-yl)-4-methylpent-3-enyl] acetate Chemical compound C1=CC(O)=C2C(=O)C([C@@H](OC(C)=O)CC=C(C)C)=CC(=O)C2=C1O WNFXUXZJJKTDOZ-HNNXBMFYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 235000019232 alkannin Nutrition 0.000 description 1
- UNNKKUDWEASWDN-UHFFFAOYSA-N alkannin Natural products CC(=CCC(O)c1cc(O)c2C(=O)C=CC(=O)c2c1O)C UNNKKUDWEASWDN-UHFFFAOYSA-N 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- DKZBBWMURDFHNE-NSCUHMNNSA-N coniferyl aldehyde Chemical compound COC1=CC(\C=C\C=O)=CC=C1O DKZBBWMURDFHNE-NSCUHMNNSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- WENNXORDXYGDTP-UOUCMYEWSA-N cycloastragenol Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O)C4(C)C)[C@H]4[C@@H](O)C[C@H]3[C@]2(C)C[C@@H]1O WENNXORDXYGDTP-UOUCMYEWSA-N 0.000 description 1
- WENNXORDXYGDTP-UHFFFAOYSA-N cyclosiversigenin Natural products O1C(C(C)(O)C)CCC1(C)C1C2(C)CCC34CC4(CCC(O)C4(C)C)C4C(O)CC3C2(C)CC1O WENNXORDXYGDTP-UHFFFAOYSA-N 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- NEKNNCABDXGBEN-UHFFFAOYSA-L disodium;4-(4-chloro-2-methylphenoxy)butanoate;4-(2,4-dichlorophenoxy)butanoate Chemical compound [Na+].[Na+].CC1=CC(Cl)=CC=C1OCCCC([O-])=O.[O-]C(=O)CCCOC1=CC=C(Cl)C=C1Cl NEKNNCABDXGBEN-UHFFFAOYSA-L 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002207 flavanone derivatives Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000001261 florigenic effect Effects 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- MYJXWCIZOOKQLK-UHFFFAOYSA-N kakkalide Natural products COc1cc2C(=O)C(=COc2cc1OC3OC(COC4OCC(O)C(O)C4O)C(O)C(O)C3O)c5ccc(O)cc5 MYJXWCIZOOKQLK-UHFFFAOYSA-N 0.000 description 1
- OWOLPTZIAWJNPY-UHFFFAOYSA-N kakkatin Natural products COc1ccc2OC=C(C(=O)c2c1O)c3ccc(O)cc3 OWOLPTZIAWJNPY-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- ZLEFBGVPYZUUGI-UHFFFAOYSA-N methyl benzoate;2-methylbenzoic acid Chemical compound COC(=O)C1=CC=CC=C1.CC1=CC=CC=C1C(O)=O ZLEFBGVPYZUUGI-UHFFFAOYSA-N 0.000 description 1
- CCRCUPLGCSFEDV-BQYQJAHWSA-N methyl trans-cinnamate Chemical compound COC(=O)\C=C\C1=CC=CC=C1 CCRCUPLGCSFEDV-BQYQJAHWSA-N 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 235000019991 rice wine Nutrition 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- WNFXUXZJJKTDOZ-UHFFFAOYSA-N shikonin acetate Natural products C1=CC(O)=C2C(=O)C(C(OC(C)=O)CC=C(C)C)=CC(=O)C2=C1O WNFXUXZJJKTDOZ-UHFFFAOYSA-N 0.000 description 1
- AHVGRDMMMLZUJT-FHDYCXBFSA-N sissotrin Natural products COc1ccc(cc1)C2=COc3cc(O[C@@H]4C[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)cc(O)c3C2=O AHVGRDMMMLZUJT-FHDYCXBFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- PTDAHAWQAGSZDD-IOVCITQVSA-N soyasaponin I Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H](O[C@@H]([C@@H](O)[C@@H]2O)C(O)=O)O[C@@H]2[C@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(CC[C@@]6(C)[C@H](O)CC(C)(C)C[C@H]6C5=CC4)C)(C)CC3)(C)CC2)(C)CO)O[C@H](CO)[C@H](O)[C@@H]1O PTDAHAWQAGSZDD-IOVCITQVSA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- CMUNUTVVOOHQPW-ZCFIWIBFSA-N stachydrine Natural products C[N+]1(C)CCC[C@@H]1C([O-])=O CMUNUTVVOOHQPW-ZCFIWIBFSA-N 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- VWDLOXMZIGUBKM-AUGXRQBFSA-N stigmasterol 3-O-beta-D-glucoside Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VWDLOXMZIGUBKM-AUGXRQBFSA-N 0.000 description 1
- VWDLOXMZIGUBKM-UHFFFAOYSA-N stigmasterol-3beta-O-D-glucoside Natural products C1CC2(C)C3CCC4(C)C(C(C)C=CC(CC)C(C)C)CCC4C3CC=C2CC1OC1OC(CO)C(O)C(O)C1O VWDLOXMZIGUBKM-UHFFFAOYSA-N 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- KCDXJAYRVLXPFO-UHFFFAOYSA-N syringaldehyde Chemical compound COC1=CC(C=O)=CC(OC)=C1O KCDXJAYRVLXPFO-UHFFFAOYSA-N 0.000 description 1
- COBXDAOIDYGHGK-UHFFFAOYSA-N syringaldehyde Natural products COC1=CC=C(C=O)C(OC)=C1O COBXDAOIDYGHGK-UHFFFAOYSA-N 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- DKZBBWMURDFHNE-UHFFFAOYSA-N trans-coniferylaldehyde Natural products COC1=CC(C=CC=O)=CC=C1O DKZBBWMURDFHNE-UHFFFAOYSA-N 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了具有保肝解酒作用的保健品,由下述重量配比的原料制成:葛根花2-5份、高良姜1-3分、菊花1-3份、黄芪0.5-1份、当归0.5-1份、枸杞子0.5-1份、紫草0.5-1份、竹茹0.5-1份。该保健品具有良好的保护肝脏、分解酒精、及抗疲劳、增强机体免疫功能等作用,且有利于人身体的吸收,安全无毒副作用。本发明还公开了一种上述保健品的制备方法。
Description
技术领域
本发明属于保健品技术领域,特别涉及一种具有保肝解酒作用的保健品及其制备方法。
背景技术
酒对人体有广泛的药理作用,急性大量饮酒可引起恶心、呕吐、记忆力减退、注意力不集中、精细运动能力受损和情绪不稳定,严重时甚至可因呼吸肌麻痹而导致死亡。长期饮酒可引起精神障碍、胃溃疡以及脂肪肝、酒精性肝炎、肝硬化等疾病,有资料表明食道癌、肝癌发病率的升高似乎也与饮酒有关。近年来我国酗酒和酒精中毒者日益增多,严重影响人们身体健康和家庭、社会的稳定。因此开发安全有效的解酒药物/保健品受到各国政府和人民的普遍重视。
目前西方国家开发的解酒产品以合成物质为主,而亚洲国家则侧重天然植物的研究开发。乙醇在人体内由消化道吸收,主要在肝脏代谢,在生理条件下经乙醇脱氢酶代谢为乙醛,进而转化为乙酸,进入体循环。此外,肝脏中还存在微粒体乙醇氧化酶系等代谢系统,主要在摄取高剂量乙醇时发挥作用。乙醇在代谢过程中诱发自由基的产生,对肝脏等多个器官造成损害。乙醇脂溶性较大,可透过血脑屏障人脑,其在脑内的浓度与血中浓度差别不大,因此可以根据血中乙醇浓度推断酒醉状态。
因此,解酒的途径就要从降低患者血中乙醇及其代谢产物的浓度、减轻其对各器官的损伤着手。根据乙醇在体内的代谢特点,当前的药物主要从两方面发挥解酒作用:一是抑制酒精的胃肠吸收,加强乙醇在胃肠道的首过效应,降低血中的乙醇浓度;二是药物直接作用于肝代谢酶系,加速乙醇及其代谢产物的消除速率,减轻其对组织和细胞的损害。
发明内容
本发明的主要目的是提供一种具有保肝解酒作用的保健品,该保健品具有良好的保护肝脏、分解酒精、及抗疲劳、增强机体免疫功能等作用,且有利于人身体的吸收,安全无毒副作用。
本发明还提供了一种上述具有保肝解酒作用的保健品的制备方法。
本发明解决其技术问题所采用的技术方案是:
具有保肝解酒作用的保健品,由下述重量配比的原料制成:
葛根花2-5份、高良姜1-3分、菊花1-3份、黄芪0.5-1份、当归0.5-1份、枸杞子0.5-1份、紫草0.5-1份、竹茹0.5-1份。
上述具有保肝解酒作用的保健品可采用下述方法制备:
将以上原料粉碎,按比例混匀,加入炼蜜,制成大蜜丸,即得。
本发明营养食品的各原料中:
葛根花中含多种挥发油,其中性油中含1-辛烯-3-醉(1-octen-3-ol),丁香油酚(eugenol),芳樟醇(linalool),酸性油中得苯甲酸甲酯(methyl benzoate),丙酸甲酯(methylpropionate),异戊酸甲酯(methyl isovalerate),正己酸甲酯(methylcaproate)。另外得尼泊尔鸢尾黄酮(irisolidonce),染料木素(genistein),大豆素(daidzein),槲皮素(quercetin),葛花苷(kakkalide),鹰嘴豆芽素(biochanin)A,刺芒柄花素(formononetin),芒柄花苷(ononin),降紫香苷(sissotrin),又从中提得三萜皂苷:槐花二醇(sophoradiol),槐花皂苷(kaikasaponin)III。此外,还分得β-谷甾醇(β-sitosterol),β-谷甾醇-3-O-β-D-葡萄糖(β-sitosterol-3-O-β-D-glucose)。从中国购买葛花中分离得葛花异黄酮,即6,4′-二羟基-7-甲氧基异黄酮(kakkatin)。功能主治为解酒止渴。用于酒醉烦渴。解酒醒脾。治伤酒发热烦渴,不思饮食,呕逆吐酸,吐血,肠风下血。
高良姜含多种二苯基庚烷类化合物:姜黄素(curcumin)、二氢姜黄素(dihydrocurcumin)、六氢姜黄素(hexahydrocurcumin)、八氢姜黄素(octahydrocurcumin)、(3R,5R)-1-(4-羟苯基)-7-苯基-3,5庚二醇[(3R,5R)-1-(4)-hydroxyphenyl]-7-phenylheptane-3,5-diol]、5-羟基-7-(4-羟基-3-甲氧基苯基)-1-苯基-3-庚酮[5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-phenyl-3-heptanone]、1,7-二苯基-4-庚烯-3-酮(1,7-diphenyl-hept-4-en-3-one)、7-(4-羟基-3-甲氧基苯基)-1-苯基-4-庚烯-3-酮[7-(4-hydroxy-3-methoxyphenyl)-1-phenylhept-4-en-3-one]、1,7-二苯基-5-羟基-3-庚酮(1,7-diphenyl-5-hydroxy-3-heptanone)、表六氢姜黄素(epihexahydrocurcumin)等。还含黄酮类化合物:高良姜素(galangin)、槲皮素(quercetin)、山柰酚(kaempferol)、山柰素(kaempferide)、异鼠李素(isorhamnetin)、槲皮素-5-甲醚(quercetin-5-methylether)、高良姜素-3-甲醚(galangin-3-methyl ether)等。又含挥发油,内有:桉叶素(1,8-cineole)、丁香油酚(eugenol)、桂皮酸甲酯(methylcinnamate)等。根尚含β-谷甾醇-β-葡萄糖苷(β-sitosterol-β-glucoside)、豆甾醇葡萄糖苷(stigmasterol-β-glucoside)、菜油甾醇葡萄糖苷(campestrol-β-glucoside)等。高良姜水提物和醚提物能显著对抗小鼠水浸应激型溃疡和大鼠盐酸损伤性溃疡;水提物对小鼠胃肠道推进有明显抑制,两种提取物都能显著对抗蓖麻油引起的腹泻,其水提物还对番泻叶引起的腹泻有效。水提物有协同转氨酶升高作用。两种提取物对麻醉大鼠均有明显利胆作用,醚提物作用较强。在热极法和乙酸扭体试验中,两种提取物都有明显镇痛作用。对心绞痛具有快速止痛作用,对轻度使肾上腺素引起的微动脉血流停止或减慢有推迟作用。对管径收缩时间有推迟作用。在对给肾上腺素10分钟后使管径有恢复作用(对照组继续收缩),还有对微动脉轻度收缩作用。
菊花含有有效化学成分,如腺嘌呤、胆碱、水苏碱等,从菊中提炼出来的挥发油,含有菊花酮、龙脑、乙酸龙脑酯等。药理实验证明,白菊煎剂对宋氏痢疾杆菌、变形杆菌、伤寒杆菌、副伤寒杆菌、绿脓杆菌、大肠杆菌及霍乱弧菌等都有抑制作用。常服菊花煎剂,对心脏有明显扩冠和增加冠脉流量,能降低血清甾醇和三酸甘油脂,并能降压预防心绞痛。白菊还可代茶,其色、香、味不亚于龙井茶。经常服用,能增强毛细血管抵抗力、抑制毛细血管的通性,起到抗炎强身作用。
黄芪主要含有皂苷、黄酮、多糖以及氨基酸等几类成分。1皂苷类在黄芪及其同属近缘共分离出四十余种三萜皂苷,其结构为四环三萜及五环三萜苷类,苷的糖多为葡萄糖、半乳糖、鼠李糖,多接于苷元3,6位。有些苷的某些羟基乙酰化,膜荚黄芪中分离出黄芪苷I、黄芪苷II。在膜荚黄芪中有乙酰黄芪苷I、黄芪苷I~VIII、异黄芪苷I~II、黄芪皂苷乙、环黄芪醇和大豆皂苷等;膜荚黄芪皂苷呆板厂蒙古黄芪中有黄芪苷1、I、W和大豆皂苷1。多糖类具有免疫促进作用。黄酮类主要包括异黄酮类、二氢黄酮类,主要有山奈素、槲皮素、异鼠李素、鼠李柠檬素、熊竹素、芝柄花素、毛蕊异黄酮、芒柄花黄素及其苷类等;其苷类的糖多为葡萄糖、鼠李糖,从膜荚黄芪的茎叶中分出鼠李柠檬素3葡萄糖苷及槲皮素3葡萄糖苷。氨基酸类包括21种游离氨基酸包括天冬酰胺、刀豆氨酸、脯氨酸、精氨酸、天冬氨酸等。生物碱类包括胆碱和甜菜碱等。有机酸类主要有香草酸、阿魏酸、异阿魏酸、对羟苯基丙烯酸、咖啡酸、绿原酸及棕榈酸。微量元素以铁、锰、锌和铷含量较大,另有报道其富含硒。还含有胡萝卜苷、叶酸、β-谷甾醇等。传统中医学认为,黄芪具有补气升阳、固表止汗、托毒排脓、利水消肿、敛疮生肌的功效。现代药理研究表明,黄芪具有增强机体免疫功能、强心降压、降血糖、利尿、抗衰老、抗疲劳、抗肿瘤、抗病毒、抗突变、保肝、镇静、镇痛等作用。
当归含蒿本内脂、正丁烯酰内酯、阿魏酸、烟酸、蔗糖和多种氨基酸,以及倍半萜类化合物等。具有补血活血,调经止痛,润肠通便等功效。用于血虚萎黄,眩晕心悸,月经不调,经闭痛经,虚寒腹痛,肠燥便秘,风湿痹痛,跌扑损伤,痈疽疮疡。酒当归活血通经。用于经闭痛经,风湿痹痛,跌扑损伤。
枸杞子含有丰富的枸杞多糖、脂肪、蛋白质、游离氨基酸、牛磺酸、甜菜碱、维生素B1、B2、E、C,特别是类胡萝卜素含量很高。此外,还含有大量的矿物元素,如钾、钠、钙、镁、铁、铜、锰、锌、硒等。具有补肾益精,养肝明目,补血安神,生津止渴,润肺止咳等功效。
紫草含乙酰紫草素、β-羟基异戊酰紫草素、紫草素、β,β’-二甲基丙烯酰紫草素等。功能主治为凉血,活血,解毒透疹。用于血热毒盛、斑疹紫黑、麻疹不透、疮疡、湿疹、水火烫伤。清热凉血,用于麻疹,热病癍疹,湿疹,尿血,血淋,血痢,疮疡,丹毒,烧伤,热结便秘。
竹茹化学成分含对cAMP磷酸二酯酶抑制作用的成分:2,5二甲氧基-对-羟基苯甲醛、丁香醛、松柏醛等。另含对苯二甲酸2’-羟乙基甲基酯、木质素、纤维素等。功能主治为:清热化痰,除烦止呕。用于痰热咳嗽、胆火挟痰、烦热呕吐、惊悸失眠、中风痰迷、舌强不语、胃热呕吐、妊娠恶阻、胎动不安。
与现有技术相比,本发明的有益效果是:
本发明营养食品中各种成分搭配合理,有利于人身体的吸收,具有良好的保护肝脏、分解酒精、及抗疲劳、增强机体免疫功能等作用,安全无毒副作用。通过抑制酒精在胃肠道的吸收,降低血中的乙醇浓度,加速乙醇及其代谢产物的消除速率,从而达到调整、缓解、解除由饮酒引起的各种不适症状的作用,同时可避免酒精对肝脏的损害。
具体实施方式
下面结合具体实施方式对本发明作进一步的详细描述。
但不应将此理解为本发明上述主题的范围仅限于下述实施例。
实施例1
本实施例具有保肝解酒作用的保健品由下述重量配比的原料制成:
葛根花5份、高良姜2分、菊花1份、黄芪1份、当归1份、枸杞子0.5份、紫草0.5份、竹茹1份。
实施例2
本实施例具有保肝解酒作用的保健品由下述重量配比的原料制成:
葛根花2份、高良姜3分、菊花2份、黄芪0.5份、当归0.5份、枸杞子1份、紫草1份、竹茹0.5份。
实施例3
本实施例具有保肝解酒作用的保健品由下述重量配比的原料制成:
葛根花3份、高良姜1分、菊花3份、黄芪0.8份、当归0.6份、枸杞子0.6份、紫草0.8份、竹茹0.8份。
上述实施例1-3的营养食品均采用下述方法制备:
将各原料粉碎,按比例混匀,加入炼蜜,制成大蜜丸,即得。
Claims (2)
- 【权利要求1】具有保肝解酒作用的保健品,由下述重量配比的原料制成:葛根花2-5份、高良姜1-3分、菊花1-3份、黄芪0.5-1份、当归0.5-1份、枸杞子0.5-1份、紫草0.5-1份、竹茹0.5-1份。
- 【权利要求2】一种权利要求1所述的具有保肝解酒作用的保健品的制备方法,其特征在于:将所述的原料粉碎,按比例混匀,加入炼蜜,制成大蜜丸,即得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008103057858A CN101461526B (zh) | 2008-11-27 | 2008-11-27 | 具有保肝解酒作用的保健品及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008103057858A CN101461526B (zh) | 2008-11-27 | 2008-11-27 | 具有保肝解酒作用的保健品及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101461526A true CN101461526A (zh) | 2009-06-24 |
CN101461526B CN101461526B (zh) | 2011-12-28 |
Family
ID=40802475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008103057858A Active CN101461526B (zh) | 2008-11-27 | 2008-11-27 | 具有保肝解酒作用的保健品及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101461526B (zh) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102038057A (zh) * | 2009-10-15 | 2011-05-04 | 尹付春 | 一种滋养解酒冰茶 |
CN102526618A (zh) * | 2012-01-17 | 2012-07-04 | 张继成 | 改进型肝复康胶囊 |
CN102935197A (zh) * | 2012-11-26 | 2013-02-20 | 杨荣 | 一种口味改善型醒酒口服液及其制备方法 |
CN102940836A (zh) * | 2012-11-26 | 2013-02-27 | 杨荣 | 一种醒酒口服液 |
CN103584077A (zh) * | 2012-08-14 | 2014-02-19 | 广西玉林制药集团巨安保健品有限公司 | 一种保健食品的组合物 |
CN104126796A (zh) * | 2014-07-18 | 2014-11-05 | 吴自伟 | 一种解酒保健食品 |
CN104721698A (zh) * | 2015-02-27 | 2015-06-24 | 周舜宁 | 一种解酒中药组合物 |
CN104783031A (zh) * | 2015-04-02 | 2015-07-22 | 国药集团健康产业研究院有限公司 | 一种护肝护脑组合物 |
CN105920478A (zh) * | 2016-04-28 | 2016-09-07 | 苏州市天灵中药饮片有限公司 | 一种解酒泡腾片及其制备方法 |
CN106721793A (zh) * | 2016-12-05 | 2017-05-31 | 张俊宝 | 一种竹茹解酒保健口服液 |
CN108576814A (zh) * | 2018-04-28 | 2018-09-28 | 成都市宏智达科技有限公司 | 一种解酒合剂及其制备方法 |
CN113842461A (zh) * | 2021-11-04 | 2021-12-28 | 杭州诺莘科技有限责任公司 | 用于缓解、治疗酒精中毒、酒后不适的gabaa受体结合物、组合物及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1038216A (zh) * | 1989-06-20 | 1989-12-27 | 陈江辉 | 根治扁桃体炎口服液的配制方法 |
CN1269523C (zh) * | 2003-12-08 | 2006-08-16 | 李永胜 | 强免疫、抗病毒、预防流感、感冒的组合中药 |
-
2008
- 2008-11-27 CN CN2008103057858A patent/CN101461526B/zh active Active
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102038057A (zh) * | 2009-10-15 | 2011-05-04 | 尹付春 | 一种滋养解酒冰茶 |
CN102038057B (zh) * | 2009-10-15 | 2014-02-05 | 尹付春 | 一种滋养解酒冰茶 |
CN102526618A (zh) * | 2012-01-17 | 2012-07-04 | 张继成 | 改进型肝复康胶囊 |
CN102526618B (zh) * | 2012-01-17 | 2014-01-22 | 张继成 | 改进型肝复康胶囊 |
CN103584077A (zh) * | 2012-08-14 | 2014-02-19 | 广西玉林制药集团巨安保健品有限公司 | 一种保健食品的组合物 |
CN102935197A (zh) * | 2012-11-26 | 2013-02-20 | 杨荣 | 一种口味改善型醒酒口服液及其制备方法 |
CN102940836A (zh) * | 2012-11-26 | 2013-02-27 | 杨荣 | 一种醒酒口服液 |
CN104126796A (zh) * | 2014-07-18 | 2014-11-05 | 吴自伟 | 一种解酒保健食品 |
CN104721698A (zh) * | 2015-02-27 | 2015-06-24 | 周舜宁 | 一种解酒中药组合物 |
CN104783031A (zh) * | 2015-04-02 | 2015-07-22 | 国药集团健康产业研究院有限公司 | 一种护肝护脑组合物 |
CN104783031B (zh) * | 2015-04-02 | 2018-06-01 | 上海医药工业研究院 | 一种护肝护脑组合物 |
CN105920478A (zh) * | 2016-04-28 | 2016-09-07 | 苏州市天灵中药饮片有限公司 | 一种解酒泡腾片及其制备方法 |
CN106721793A (zh) * | 2016-12-05 | 2017-05-31 | 张俊宝 | 一种竹茹解酒保健口服液 |
CN108576814A (zh) * | 2018-04-28 | 2018-09-28 | 成都市宏智达科技有限公司 | 一种解酒合剂及其制备方法 |
CN113842461A (zh) * | 2021-11-04 | 2021-12-28 | 杭州诺莘科技有限责任公司 | 用于缓解、治疗酒精中毒、酒后不适的gabaa受体结合物、组合物及其应用 |
CN113842461B (zh) * | 2021-11-04 | 2023-08-11 | 杭州诺莘科技有限责任公司 | 用于缓解、治疗酒精中毒、酒后不适的gabaa受体结合物、组合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101461526B (zh) | 2011-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101461526B (zh) | 具有保肝解酒作用的保健品及其制备方法 | |
Chen et al. | Modifications of dietary flavonoids towards improved bioactivity: An update on structure–activity relationship | |
Bi et al. | Traditional uses, phytochemistry, and pharmacology of the genus Acer (maple): A review | |
Luan et al. | Recent advances in Camellia oleifera Abel: A review of nutritional constituents, biofunctional properties, and potential industrial applications | |
Xing et al. | Chemical constituents, biological functions and pharmacological effects for comprehensive utilization of Eucommia ulmoides Oliver | |
Al-Snafi | Medical importance of Cichorium intybus–A review | |
Koul et al. | Genus Psoralea: a review of the traditional and modern uses, phytochemistry and pharmacology | |
Yu et al. | Trichosanthis Fructus: botany, traditional uses, phytochemistry and pharmacology | |
CN105380051B (zh) | 一种解酒护肝饮料及其制备方法 | |
KR100864455B1 (ko) | 간경변, 세포 독성 개선 및 간손상 억제 활성을 갖는 혼합생약 추출물을 함유하는 간질환의 예방 및 치료용 조성물 | |
KR100968109B1 (ko) | 칼슘 화합물을 주성분으로 한 천연 원료의 숙취 해소용조성물 및 이의 제조 방법 | |
El-Tantawy | Natural products for the management of hyperuricaemia and gout: a review | |
Hu et al. | Medicinal and edible plants in the treatment of dyslipidemia: advances and prospects | |
Akbar et al. | Glycyrrhiza glabra L.(Fabaceae/Leguminosae) (Syns.: G. glandulifera Waldst. & Kit.; G. hirsuta Pall.; G. pallida Boiss. & Noe; G. violacea Boiss. & Noe) | |
CN112336815A (zh) | 一种强体防癌调理三高抗衰老组合物及其应用 | |
Kumar et al. | Traditional uses, phytochemistry, quality control and biological activities of genus Grewia | |
CN104146240B (zh) | 一种降糖降脂保健组合物及其制备方法 | |
CN105396120B (zh) | 一种治疗痘坑及凹陷性疤痕的药物 | |
CN102273679A (zh) | 一种饮料的制作方法 | |
Xu et al. | Bioactive components of Gynura divaricata and its potential use in health, food and medicine: a mini-review | |
Abdel Bar et al. | Genus Lactuca (Asteraceae): A Comprehensive Review. | |
CN104208393A (zh) | 一种用于防治鸡传染性支气管炎的中药组合物及其制备方法 | |
GHANEMI et al. | Phytochemistry and Pharmacology of Ceratonia siliqua L. leaves | |
CN103100028A (zh) | 有利于降低酒精性肝损伤危害的软胶囊及其制备方法 | |
CN104161986A (zh) | 一种用于防治禽流感的中药组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |